肝硬化门静脉血栓预测:临床、超声与止血因素的前瞻性研究
该前瞻性队列纳入369例无门静脉血栓(PVT)的肝硬化患者,全面评估临床、生化、炎症及获得性/遗传性止血指标,基线及每6个月行多普勒超声,PVT经CT确认。1、3、5年PVT累积发生率分别为1.6%、6%、8.4%;低血小板计数、门静脉血流速度(PBFV)<15 cm/sec及静脉曲张出血史为独立危险因素,止血及炎症指标与PVT无关。
要点
- 肝硬化患者1、3、5年非肿瘤性PVT发生率分别为1.6%、6%、8.4%。
- 低血小板计数、PBFV<15 cm/sec及静脉曲张出血史独立预测PVT。
- 获得性或遗传性止血异常及炎症标志物未显示预测PVT的作用。
核心结论
- 肝硬化患者PVT的预测因素主要与门静脉高压严重程度相关。
- 止血异常(遗传或获得性)及炎症标志物不支持用于预测肝硬化患者PVT。
研究设计与样本
- 前瞻性队列研究,纳入369例无PVT的肝硬化患者,基线及每6个月或临床需要时行多普勒超声,PVT经CT确认。
主要发现
- 低血小板计数、PBFV<15 cm/sec及静脉曲张出血史与PVT高风险独立相关。
- 未发现PVT与其他临床、生化、炎症及获得性或遗传性止血参数的关系。
关键数值与推荐
- PBFV<15 cm/sec与PVT高风险独立相关。
- 低血小板计数与PVT高风险独立相关。
- 静脉曲张出血史与PVT高风险独立相关。
临床怎么用
- 对肝硬化患者可结合血小板计数、PBFV及静脉曲张出血史评估PVT风险。
- 不推荐依据止血或炎症指标预测PVT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Portal vein thrombosis (PVT) is a relatively frequent event in patients with cirrhosis. While different risk factors for PVT have been reported, such as decreased portal blood flow velocity (PBFV) and parameters related with severity of portal hypertension, these are based on retrospective studies assessing only a discrete number of parameters. The aim of the current study was to evaluate the incidence and risks factors for non-tumoral PVT development in a large prospective cohort of patients with cirrhosis. METHODS: We performed an exhaustive evaluation of clinical, biochemical, inflammatory and acquired/hereditary hemostatic profiles in 369 patients with cirrhosis without PVT who were prospectively followed-up. Doppler ultrasound was performed at baseline and every 6 months or whenever clinically indicated. PVT development was always confirmed by computed tomography. RESULTS: Twenty-nine patients developed non-tumoral PVT, with an incidence of 1.6%, 6% and 8.4% at 1, 3 and 5 years, respectively. Low platelet count, PBFV <15 cm/sec and history of variceal bleeding were factors independently associated with a high PVT risk. No relationship between PVT development and any other clinical biochemical, inflammatory and acquired or hereditary hemostatic parameter was found. CONCLUSIONS: In patients with cirrhosis, the factors predictive of PVT development were mainly those related to the severity of portal hypertension. Our results do not support the role of hemostatic alterations (inherited or acquired) and inflammatory markers in the prediction of PVT in patients with cirrhosis. LAY SUMMARY: Patients with cirrhosis and more severe portal hypertension are at higher risk of non-tumoral portal vein thrombosis development. Acquired or inherited hemostatic disorders, as well as inflammatory status, do not seem to predict the development of portal vein thrombosis in patients with cirrhosis.
引用
- Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol. 2021. PMID: 34333101. doi:10.1016/j.jhep.2021.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。